Glenmark Pharmaceuticals Ltd. is a research-driven, global, integrated pharmaceutical company.
Glenmark has a diverse pipeline with several compounds in various stages of clinical development primarily focused in the therapeutic areas of oncology, respiratory, and dermatology. The company has a significant presence in branded generics across emerging economies including India. It also has a fast growing and robust US generics business. Glenmark employs over 13,500 people and has operations in over 80 countries. It has 16 manufacturing facilities across five countries and 6 R&D centres.
Glenmark is currently ranked among the World's Top - 75 Pharma & Biotech companies (SCRIP 100 – 2018 Rankings). Glenmark has also been chosen as the 'Best Company Across Emerging Markets' 2011, and recognized for the 'Best Overall Pipeline' 2011 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world. SCRIP had also recognized Glenmark as 'Best Pharma Company in the World – SME' and 'Best Company in an Emerging Market' in 2008. Other awards and recognitions received by the company include the ‘Best under a Billion Dollar companies in Asia’ for 2008 by Forbes, a leading international publication, ‘Indian Innovator Pharmaceutical Company of the Year – 2010’ by Frost & Sullivan, and Gold Patent Award 2011 in the categories of API Formulations & Export of bulk drugs (Non Biologicals) by Pharmexcil.
Headquartered in Mumbai, India, with U.S. headquarters in Mahwah, NJ, Glenmark has improved the lives of millions of patients by offering safe, affordable medications for nearly 40 years.